Myovant Sciences Grabs Priority Review for Prostate Cancer Treatment

June 23, 2020

The FDA has granted a priority review to Myovant Sciences’ relugolix as a once-daily treatment for advanced prostate cancer.

The FDA decision date for the drug is Dec. 20.  If approved, relugolix would be the first oral gonadotropin-releasing hormone (GnRH) antagonist treatment for men with advanced prostate cancer.

The company submitted a separate new drug application for relugolix last month for women with heavy menstrual bleeding associated with uterine fibroids.

View today's stories